NCT05786066View on ClinicalTrials.gov

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

March 31, 2033

Study Completion Date

March 31, 2033

Conditions
Depressive DisorderMajor Depressive DisorderBipolar DisorderPost Traumatic Stress DisorderSuicidal Ideation
Interventions
DRUG

Perampanel 6 MG

Perampanel will be administered 2.5 hours before Ketamine infusion

DRUG

Ketamine

Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.

DRUG

Placebo

Placebo will be administered 2.5 hours before Ketamine infusion

Trial Locations (1)

06516

RECRUITING

VA Connecticut Healthcare System, West Haven

All Listed Sponsors
collaborator

American Foundation for Suicide Prevention

OTHER

collaborator

National Center for PTSD

FED

collaborator

VA Connecticut Healthcare System

FED

lead

Yale University

OTHER

NCT05786066 - The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects | Biotech Hunter | Biotech Hunter